Amphastar Pharmaceuticals (AMPH) Assets Average (2014 - 2026)

Amphastar Pharmaceuticals' Assets Average history runs 13 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 2.3% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 2.3% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 3.77% from the prior year.
• Assets Average declined to $1.6 billion in Q1 2026 per AMPH's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.6 billion in Q4 2025 and bottomed at $693.9 million in Q1 2022.
• The 5-year median for Assets Average is $1.5 billion (2023), against an average of $1.3 billion.
• Across the five-year window, Assets Average jumped 108.18% in 2023 and increased 2.13% in 2024, its largest moves.
• Year by year, Assets Average stood at $734.3 million in 2022, then soared by 108.18% to $1.5 billion in 2023, then increased by 2.13% to $1.6 billion in 2024, then climbed by 5.54% to $1.6 billion in 2025, then slipped by 0.55% to $1.6 billion in 2026.
• Per Business Quant, the three latest AMPH Assets Average figures stand at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025).